Silexion Therapeutics Warrant
SLXNW
22 hedge funds and large institutions have $83.1K invested in Silexion Therapeutics Warrant in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0% more funds holding
Funds holding: 22 → 22 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
3.24% less ownership
Funds ownership: 43.16% → 39.93% (-3.2%)
35% less capital invested
Capital invested by funds: $128K → $83.1K (-$44.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$755 |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$444 |
| 3 |
Goldman Sachs
New York
|
+$163 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.75K |
| 2 |
CS
Clear Street
New York
|
-$21 |
SLXNW Hedge Fund Activity: Q4 2025 in Review
22 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q4 2025, worth a combined $83.1K — down 35% from $128K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SLXNW positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $755. The largest seller was Susquehanna International Group, exiting entirely with an estimated $7.75K sold.
- 22 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $83.1K of Silexion Therapeutics Warrant stock for Q4 2025, down 35% quarter-over-quarter.
- 2 funds opened new Silexion Therapeutics Warrant positions in Q4 2025 and 1 closed out, a net change of +1 holder.
- The largest Silexion Therapeutics Warrant buyer in Q4 2025 was HRT Financial, an estimated $755 added.
- The largest Silexion Therapeutics Warrant seller in Q4 2025 was Susquehanna International Group, an estimated $7.75K sold.
Based on aggregated 13F filings for Q4 2025.